Traditional, Cultural, and Nutraceutical Aspects of Cannabis in India

Jeyabalan, G.; Moss, Sarah; Parise, Rachel; Nadar, Rishi M.; Pathak, Suhrud; Ramesh, Sindhu; Govidarajulu, Manoj; Moore, Timothy M.; Agrawal, Dinesh Chandra; Dhanasekaran, Muralikrishnan

doi:10.1007/978-981-16-8822-5_15

Cited by 3 publications

(2 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cannabidiol is regulated by the Central Bureau of Narcotics under the Narcotic Drugs And Psychotropic Substances, Act, of 1985. It is therefore not listed in the CDSCO drug list however historically, India has continued to produce and use Cannabis for medicinal and nutritional purpose and various indigenous systems of medicine such as Ayurveda, Unani, Siddha also documents the use of cannabis in treating many disorders [ 36 ]. Thus Cannabidiol should be easily available to patients in India.…”

Section: Discussionmentioning

confidence: 99%

Assessment of the availability of repurposed orphan drugs in India

Rajueni,

Chakraborty Choudhury

2023

PLOS Glob Public Health

View full text Add to dashboard Cite

India has a massive burden of rare diseases (RDs), with an estimated 96 million people living with RDs but limited options for treatment. Repurposing drugs used for other common conditions are essential alternative for RDs due to their cost-effectiveness and reduced timeline. India’s patent regime prevents the evergreening of drugs, and a large generic manufacturing industry provides ample opportunity to explore the potential of repurposed drugs for treating RDs, known as repurposed orphan drugs (ROD). However, there is no portal or other source for information on orphan drugs in India. This study assesses the availability of RODs in India through quantitative analysis. In the absence of a separate orphan drug designation in India, we consider USFDA-approved orphan-designated products as the reference. We searched USFDA-approved RODs in recognized sources in India, such as CDSCO, AYUSH gazette, FSSAI, and Indian Pharmacopeia, which provides a list of drugs approved for marketing in India. We classified the drugs into separate groups based on their record from different sources and explored the regulatory implications of the differential representations. We found that almost 76% of the USFDA-approved RODs are listed in one of the Indian regulatory bodies’ records either in the same form (61%) or in a different fixed-dose combination. For 67 drugs no information was found, these drugs have to be imported for use. Only 17 of the 43 RDs mentioned in the National Policy for Rare Diseases, matched the indications listed for approval of one of the 279 RODs identified in the study. This underscores the scarcity of RD treatment and the pressing need for accessibility in India. This information on RODs will help relevant stakeholders to efficiently manage RDs in India. The study also highlights existing gaps in Indian regulatory databases that limits access to accurate information about the availability of drugs.

show abstract

Section: Discussionmentioning

confidence: 99%

Assessment of the availability of repurposed orphan drugs in India

Rajueni,

Chakraborty Choudhury

2023

PLOS Glob Public Health

View full text Add to dashboard Cite

show abstract

“…Furthermore, other ancient therapeutic methods unique to India, such as Ayurveda, Siddha, and Unani, demonstrate the widespread usage of cannabis in treating a variety of illnesses. Cannabis cultivation and application of various components of the plant such as the flowers, leaves (and the resinous materials obtained from them), fruit, young twigs, and stalk or stem, have a long and continuous history in India, dating back centuries [37]. The five-finger leaves are worshipped and offered to Lord Shiva in various temples every day in the region, along with fruit.…”

Section: Recreation Cultural and Sacredmentioning

confidence: 99%

An Ethnobotanical Survey of Plants Used by Communities around Jaunsar-Bawar Region of Uttarakhand, India

Kanika,

Panda

2024

Asian J. Env. Ecol.

View full text Add to dashboard Cite

The Jaunsar Bawar region of Uttarakhand, India, is well-known for its rich biodiversity and cultural history, which is inseparably, connected through traditional ecological knowledge (TEK) and ethnobotanical traditions. This work explores the ethnobotanical knowledge and practices amongst the indigenous communities residing in the JaunsarBawar region, of 11 villages in three tehsils: Kalsi, Tyuni, and Chakrata of Uttarakhand state of India. With extensive field studies, literature reviews, surveys using standard questionnaires, and semi-structured interviews with local inhabitants including Vaidyas, Hakeem, and forest government officials, the study tends to document the rich biodiversity of the region and comprehend the relationship between humans and plants. It documents and explores the traditional usage of 65 plant species of different growth habits and forms for medicine, timber, food, fodder, culinary, rituals, and other purposes. Insights of the study aid in the documentation of local plant species and indigenous wisdom of plant use across generations in the tribal region.

show abstract

Assessing the availability of Repurposed Orphan Drugs in India

Rajueni

Choudhury

2022

Preprint

View full text Add to dashboard Cite

India has a massive burden of rare diseases (RDs), estimated to be around 96 million living patients but limited options for treatment. Drugs used for RDs are known as Orphan Drugs. Globally, 95% of RDs do not have an approved drug for treatment. Novel orphan drugs are characteristically expensive and out of reach for most Indian patients. Repurposing drugs used for other common conditions have been considered an essential alternative for RDs due to their cost-effectiveness and reduced timeline resulting in higher success rates than novel drugs. India's patent regime prevents the evergreening of drugs, and a large generic manufacturing industry provides ample opportunity to explore the potential of repurposed drugs for treating RDs. However, information on the availability of repurposed orphan drugs (RODs) in India is limited. Also, there is no portal for information on orphan drugs in India. This study assesses the availability of RODs in India through quantitative empirical analysis. In the absence of a separate orphan drug designation in India, we consider USFDA-approved orphan-designated products as the reference. We searched for the availability of FDA-approved RODs in recognized sources in India, such as CDSCO, AYUSH gazette, and Indian Pharmacopeia, which provides a list of drugs approved for marketing in India. We classified the drugs into separate groups based on their availability in different sources and explored the regulatory implications of the differential representations. We found that 76% of RODs approved by the USFDA are entirely or partially available in India. Information on RODs will help relevant stakeholders in the better management of RDs in India.

show abstract

Traditional, Cultural, and Nutraceutical Aspects of Cannabis in India

Cited by 3 publications

References 17 publications

Assessment of the availability of repurposed orphan drugs in India

Assessment of the availability of repurposed orphan drugs in India

An Ethnobotanical Survey of Plants Used by Communities around Jaunsar-Bawar Region of Uttarakhand, India

Assessing the availability of Repurposed Orphan Drugs in India

Contact Info

Product

Resources

About